APA (7th ed.) Citation

L, V., JS, L., RR, d. H., HM, V., VW, v. H., HJ, B., & EF, S. (2010). CD133+ circulating haematopoietic progenitor cells predict for response to sorafenib plus erlotinib in non-small cell lung cancer patients. British journal of cancer, 102(2), 268. https://doi.org/10.1038/sj.bjc.6605477

Chicago Style (17th ed.) Citation

L, Vroling, Lind JS, de Haas RR, Verheul HM, van Hinsbergh VW, Broxterman HJ, and Smit EF. "CD133+ Circulating Haematopoietic Progenitor Cells Predict for Response to Sorafenib Plus Erlotinib in Non-small Cell Lung Cancer Patients." British Journal of Cancer 102, no. 2 (2010): 268. https://doi.org/10.1038/sj.bjc.6605477.

MLA (9th ed.) Citation

L, Vroling, et al. "CD133+ Circulating Haematopoietic Progenitor Cells Predict for Response to Sorafenib Plus Erlotinib in Non-small Cell Lung Cancer Patients." British Journal of Cancer, vol. 102, no. 2, 2010, p. 268, https://doi.org/10.1038/sj.bjc.6605477.